Gupta A, Fujita W, Gomes I, Bobeck E, Devi L A
Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Br J Pharmacol. 2015 Jan;172(2):704-19. doi: 10.1111/bph.12833. Epub 2014 Sep 5.
Opioid receptor function is modulated by post-activation events such as receptor endocytosis, recycling and/or degradation. While it is generally understood that the peptide ligand gets co-endocytosed with the receptor, relatively few studies have investigated the role of the endocytosed peptide and peptide processing enzymes in regulating receptor function. In this study, we focused on endothelin-converting enzyme 2 (ECE2), a member of the neprilysin family of metallopeptidases that exhibits an acidic pH optimum, localizes to an intracellular compartment and selectively processes neuropeptides including opioid peptides in vitro, and examined its role in modulating μ receptor recycling and resensitization.
The effect of ECE2 inhibition on hydrolysis of the endocytosed peptide was examined using thin-layer chromatography and on μ opioid receptor trafficking using either elisa or microscopy. The effect of ECE2 inhibition on receptor signalling was measured using a cAMP assay and, in vivo, on antinociception induced by intrathecally administered opioids by the tail-flick assay.
The highly selective ECE2 inhibitor, S136492, significantly impaired μ receptor recycling and signalling by only those ligands that are ECE2 substrates and this was seen both in heterologous cells and in cells endogenously co-expressing μ receptors with ECE2. We also found that ECE2 inhibition attenuated antinociception mediated only by opioid peptides that are ECE2 substrates.
These results suggest that ECE2, by selectively processing endogenous opioid peptides in the endocytic compartment, plays a role in modulating opioid receptor activity.
This article is part of a themed section on Opioids: New Pathways to Functional Selectivity. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2015.172.issue-2.
阿片受体功能受激活后事件的调节,如受体内吞、再循环和/或降解。虽然一般认为肽配体与受体共同内吞,但相对较少的研究探讨了内吞肽和肽加工酶在调节受体功能中的作用。在本研究中,我们聚焦于内皮素转化酶2(ECE2),它是金属肽酶中性肽链内切酶家族的成员,最适pH呈酸性,定位于细胞内区室,在体外能选择性加工包括阿片肽在内的神经肽,并研究了其在调节μ受体再循环和再敏化中的作用。
使用薄层色谱法检测ECE2抑制对内吞肽水解的影响,使用酶联免疫吸附测定法(ELISA)或显微镜检测其对μ阿片受体转运的影响。使用环磷酸腺苷(cAMP)检测法测定ECE2抑制对受体信号传导的影响,并在体内通过甩尾试验检测其对鞘内注射阿片类药物诱导的抗伤害感受的影响。
高度选择性的ECE2抑制剂S136492仅对那些作为ECE2底物的配体,显著损害μ受体的再循环和信号传导,这在异源细胞以及内源性共表达μ受体和ECE2的细胞中均可见。我们还发现,ECE2抑制仅减弱由作为ECE底物的阿片肽介导的抗伤害感受。
这些结果表明,ECE2通过在内吞区室中选择性加工内源性阿片肽,在调节阿片受体活性中发挥作用。
本文是关于阿片类药物:功能选择性新途径主题部分的一部分。若要查看本部分的其他文章,请访问http://dx.doi.org/10.1111/bph.2015.172.issue-2 。